(Q43996549)

28 November 2017

title

Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study (English)

1 reference

28 November 2017

1 reference

J Rippin

1

1 reference

28 November 2017

S C Bain

series ordinal

2

1 reference

28 November 2017

A H Barnett

series ordinal

3

1 reference

28 November 2017

DETAIL study

series ordinal

4

1 reference

28 November 2017

language of work or name

1 reference

1 May 2002

1 reference

Journal of Diabetes and its Complications

28 November 2017

published in

1 reference

28 November 2017

volume

16

1 reference

28 November 2017

issue

3

1 reference

28 November 2017

page(s)

195-200

1 reference

Diabetic nephropathy in type 1 (insulin-dependent) diabetes: An epidemiological study

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900165-9

7 January 2021

Short and long term effects of antihypertensive therapy in the diabetic rat

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900165-9

7 January 2021

Continuation of initial antihypertensive medication after 1 year of therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900165-9

7 January 2021

Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900165-9

7 January 2021

Diabetes mellitus and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900165-9

7 January 2021

Control of glomerular hyperfiltration and renal hypertrophy by an angiotensin converting enzyme inhibitor prevents the progression of renal damage in hypertensive diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900165-9

7 January 2021

Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900165-9

7 January 2021

Contractile properties of afferent and efferent arterioles

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900165-9

7 January 2021

Historic perspectives on the relative contributions of diastolic and systolic blood pressure elevation to cardiovascular risk profile

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900165-9

7 January 2021

The epidemiology of impaired glucose tolerance and hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900165-9

7 January 2021

Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900165-9

7 January 2021

The diabetic patient with hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900165-9

7 January 2021

ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900165-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900165-9

1 reference

7 January 2021

Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900165-9

7 January 2021

Prevention of diabetic renal disease with special reference to microalbuminuria

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900165-9

7 January 2021

Progression of overt nephropathy in non-insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900165-9

7 January 2021

Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900165-9

7 January 2021

Diabetic nephropathy in type II diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900165-9

7 January 2021

Long-term treatment with either enalapril or nitrendipine stabilizes albuminuria and increases glomerular filtration rate in non-insulin-dependent diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900165-9

7 January 2021

Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900165-9

7 January 2021

Effects of UP269-6, a New Angiotensin II Receptor Antagonist, and Captopril on the Progression of Rat Diabetic Nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900165-9

7 January 2021

Vascular complications in relation to ethnicity in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900165-9

7 January 2021

Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900165-9

7 January 2021

Effects of specific antagonists of angiotensin II receptors and captopril on diabetic nephropathy in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900165-9

7 January 2021

Pathogenesis of diabetic microangiopathy. The hemodynamic view

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900165-9

7 January 2021

Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1056-8727%2801%2900165-9

7 January 2021

10.1016/S1056-8727(01)00165-9

Identifiers

DOI

1 reference

28 November 2017

1 reference